Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1111/febs.15499

http://scihub22266oqcxt.onion/10.1111/febs.15499
suck pdf from google scholar
32738184!7436716!32738184
unlimited free pdf from europmc32738184    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32738184      FEBS+J 2020 ; 287 (17): 3677-3680
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Tumor markers as an entry for SARS-CoV-2 infection? #MMPMID32738184
  • Xia P; Dubrovska A
  • FEBS J 2020[Sep]; 287 (17): 3677-3680 PMID32738184show ga
  • Coronavirus disease 2019 (COVID-19), the highly contagious illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the globe, becoming one of the most challenging public health crisis of our times. SARS-CoV-2 can cause severe disease associated with multiple organ damage. Cancer patients have a higher risk of SARS-CoV-2 infection and death. While the virus uses angiotensin-converting enzyme 2 (ACE2) as the primary entry receptor, the recent experimental and clinical findings suggest that some tumor markers, including CD147 (basigin), can provide an additional entry for SARS-CoV-2 infection through binding to the viral spike (S) protein. In the absence of specific viral drugs, blocking of CD147 might be a way to prevent virus invasion. Identifying other target proteins is of high importance as targeting the alternative receptors for SARS-CoV-2 might open up a promising avenue for the treatment of COVID-19 patients, including those who have cancer.
  • |*COVID-19 Drug Treatment[MESH]
  • |Angiotensin-Converting Enzyme 2/genetics/metabolism[MESH]
  • |Antibodies, Monoclonal, Humanized/therapeutic use[MESH]
  • |Antibodies, Monoclonal/therapeutic use[MESH]
  • |Antineoplastic Agents, Immunological/*therapeutic use[MESH]
  • |Basigin/*antagonists & inhibitors/genetics/immunology[MESH]
  • |Biomarkers, Tumor/*antagonists & inhibitors/genetics/immunology[MESH]
  • |COVID-19/genetics/immunology/virology[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Host-Pathogen Interactions/drug effects/genetics/immunology[MESH]
  • |Humans[MESH]
  • |Neoplasms/*drug therapy/genetics/immunology/virology[MESH]
  • |Protein Binding[MESH]
  • |Receptors, Virus/genetics/metabolism[MESH]
  • |SARS-CoV-2/drug effects/immunology/pathogenicity[MESH]
  • |Severity of Illness Index[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box